Movement Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 12, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

The Adamas Pharmaceuticals agent has a PDUFA action date of February 1, 2021, as a treatment for off episodes in patients with Parkinson disease who are receiving levodopa-based therapy.

Post-hoc data presented at the EAN Congress suggest patients with dyskinesia prior to starting treatment on the Kyowa Kirin agent were more likely to experience dyskinesia as an adverse event during treatment.

Incident impulse control disorder behaviors through the 5-year follow-up period were correlated with dopamine agonist use and depression, but not with age.

The professor and head of the department of neurology at the University of Minnesota spoke to the recent findings of a study of Boston Scientific's multiple independent contact current-controlled device for deep brain stimulation.

The professor and head of the department of neurology at the University of Minnesota discussed what multiple independent contact current-controlled devices offer physicians conducting deep brain stimulation.

From post-implantation screening to 3 months, those in the active treatment arm reported a mean improvement of 3.03 more hours of on time than the control group with Boston Scientific’s deep brain stimulation device.

Neurology News Network for the week ending May 30, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

The drug is the first on-demand off episode treatment to be administered sublingually.